Question follow-through · 119737
Neurological Diseases: Drugs
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in facilitating patient access to new treatments for neuromuscular diseases.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 10 Mar 2026
- Target answer date
- 16 Mar 2026
- Answer
- 17 Mar 2026 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Integrated Care Boards: Correspondence · 16 Mar 2026
- Independent Review into Mental Health Conditions, ADHD and Autism · 17 Mar 2026
- Independent Review into Mental Health Conditions, ADHD and Autism · 17 Mar 2026
- NHS: Drugs · 17 Mar 2026
- NHS: Drugs · 23 Mar 2026
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
10 Mar 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in facilitating patient access to new treatments for neuromuscular diseases.
16 Mar 2026
Target answer date
Date supplied by the official written-questions record.
17 Mar 2026
Answer published
The Medicines and Healthcare products Regulatory Agency (MHRA) supports access to treatments for people living with neuromuscular diseases. The majority of neuromuscular diseases are defined as rare diseases. On the 2 November 2025, the MHRA published a p...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Integrated Care Boards: Correspondence
16 Mar 2026 · To ask the Secretary of State for Health and Social Care, what the average time taken was for Integrated Care Boards to respond to correspondence from hon. Members in the latest period for which data is available.
Independent Review into Mental Health Conditions, ADHD and Autism
17 Mar 2026 · To ask the Secretary of State for Health and Social Care, to set out a timeline for the process and completion of the independent review of the prevalence of and support for mental health conditions, ADHD and autism announced on 4 December 2025.
Independent Review into Mental Health Conditions, ADHD and Autism
17 Mar 2026 · To ask the Secretary of State for Health and Social Care, what will the independent review of the prevalence of and support for mental health conditions, ADHD and autism be used for.
NHS: Drugs
17 Mar 2026 · To ask the Secretary of State for Health and Social Care, what progress his Department has made on the review of early access to medicines.
NHS: Drugs
23 Mar 2026 · To ask the Secretary of State for Health and Social Care, from what date the National Institute of Clinical Excellence will be authorised to apply an increased cost-effectiveness threshold of £25,000 - £35,000 per quality-adjusted life year.
Breast Cancer
23 Mar 2026 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the completeness and consistency of data recorded on people diagnosed with secondary breast cancer in NHS trusts.
Breast Cancer
23 Mar 2026 · To ask the Secretary of State for Health and Social Care, with reference to the Cancer Plan, what progress his Department has made on defining and counting recurrent breast cancers.
Meningitis: Vaccination
10 Apr 2026 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of extending eligibility for the meningococcal B vaccination to children and young people who were not eligible for the routine infant immunisati
Maternity Services: Strategic Lawsuits against Public Participation
10 Apr 2026 · To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Secretary of State for Justice on protecting maternity safety campaigners from Strategic Lawsuit Against Public Participation (SLAPPs).
NHS: Recruitment
27 Apr 2026 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the treatment of NHS staff employed on honorary contracts in recruitment processes during periods of hiring freezes; and whether such staff are classi
Meningitis: Vaccination
15 May 2026 · To ask the Secretary of State for Health and Social Care, with reference to the response of 20 April 2026 to question 125947; what progress has been made on receiving independent expert advice from the JCVI on the meningococcal B vaccination programme, in
Maternity Services: Reviews
15 May 2026 · To ask the Secretary of State for Health and Social Care, if he will make it his policy to produce a set of specific local recommendations for each trust included in the Amos review of maternity and neonatal care following the publication of the National